A New Day Begins With Spravato

Clouds in Sky

FDA Approved

IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT (AD) FOR TREATMENT-RESISTANT DEPRESSION (TRD) IN ADULTS¹

The first and only NMDA receptor antagonist approved for TRD in adults

SPRAVATO™ hypothesized mechanism of action

Studied in more than 1700 adult patients with treatment-resistant depression

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS

1  2

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS

References:

1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.

2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.

Indication:
SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.​

SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO™ as an anesthetic agent have not been established.

Use The Link Below To Learn More About Important Safety Information...

BBB.png
OhioMHAS.png
JointCommision.png
MHAC.png
NAMI_Blue.png

© 2020 Charak Center for Health and Wellness. All Rights Reserved.  

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
89251499_102801501340964_532424517042044